[1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF

(19)

(11)

EP 2 650 293 A8

(12)	CORRECTED EUROPEAN PATENT APPLICATION
	published in accordance with Art. 153(4) EPC

(15)	Correction information:
	Corrected version no 1 (W1 A1)

(48)	Corrigendum issued on:
	25.12.2013 Bulletin 2013/52

(88)	Date of publication A3:
	16.10.2013 Bulletin 2013/42

(43)	Date of publication:
	16.10.2013 Bulletin 2013/42

(21)	Application number: 11846471.8

(22)	Date of filing: 08.12.2011

(51)

International Patent Classification (IPC):

C07D 487/04^(2006.01)
A61P 35/00^(2006.01)

A61K 31/53^(2006.01)
A61P 35/02^(2006.01)

(86)	International application number:
	PCT/CN2011/002052

(87)	International publication number:
	WO 2012/075683 (14.06.2012 Gazette 2012/24)

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

08.12.2010 CN 201010579221

(71)	Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
	Shanghai 201203 (CN)

(72)	Inventors:
	DUAN, Wenhu Pudong Shanghai 201203 (CN) GENG, Meiyu Pudong Shanghai 201203 (CN) CHEN, Fang Pudong Shanghai 201203 (CN) AI, Jing Pudong Shanghai 201203 (CN) CHEN, Yi Pudong Shanghai 201203 (CN) ZHAN, Zhengsheng Pudong Shanghai 201203 (CN) LV, Yongcong Pudong Shanghai 201203 (CN) WANG, Ying Pudong Shanghai 201203 (CN) DING, Jian Pudong Shanghai 201203 (CN)

(74)	Representative: HOFFMANN EITLE
	Patent- und Rechtsanwälte Arabellastrasse 4 81925 München 81925 München (DE)

(54)	[1,2,4]TRIAZOLO[4,3-B][1,2,4]TRIAZINE COMPOUND, PREPARATION METHOD AND USE THEREOF

(57) The present invention relates to a structurally novel [1,2,4]triazolo[4,3-b][1,2,4]triazine compounds represented by formula (I) or formula (II), pharmaceutically acceptable salts thereof, prodrugs thereof, hydrates or solvates thereof, and also relates to a preparation method of the compounds, a pharmaceutical composition comprising a therapeutically effective amount of the compounds, as well as the use thereof as protein tyrosine kinase inhibitors, particularly as c-Met inhibitors, in the preparation of medicaments for the prevention and/or treatment of diseases associated with c-Met abnormality.